BMLS partner in US$ 7.2 million research project on Parkinson’s disease
Scientists investigate how mutations in the LRRK2 gene trigger Parkinson’s disease and what possible targets there are for drugs
15 October 2020. About ten percent of Parkinson’s cases can be ascribed to mutations in the LRRK2 gene. Five research teams from the University of California in San Diego, Goethe University Frankfurt and the University of Konstanz want to explain in the next few years how mutations in the LRRK2 gene trigger Parkinson’s disease and what possible targets there are for drugs. The US-American initiative “Aligning Science Across Parkinson’s” has made the equivalent of € 6.1 million available for this project.
In the early 2000s, it was discovered that in many Parkinson’s patients a certain enzyme called LRRK2 mutates and evidently plays a significant role in five to ten percent of hereditary Morbus Parkinson and between one and five percent of the spontaneous form. LRRK2 is an enzyme that attaches phosphate groups to other proteins in the human cell and is far more active than normal in the brain cells of Parkinson’s patients, leading it to block transport processes in the cell. Many inhibitors against the LRRK2 enzyme have already been tested in the past, but they are not sufficiently effective or their side-effects are too severe.
The five teams from USA and Germany want now to elucidate in detail the enzyme’s structure and how it works in the cell and thus create a basis for the targeted production of inhibitors. A first three-dimensional structure of the LRRK2 protein was recently published by the research team in the journal Nature. The initiative “Aligning Science Across Parkinson’s”, which is backed by The Michael J. Fox Foundation for Parkinson’s Research, is supporting the project financially.
Co-Project Manager Stefan Knapp, Professor for Pharmaceutical Chemistry at Goethe University, explains: “By comparing LRRK2 mutations in Parkinson’s patients with normal LRRK2, we want to find out which tasks LRRK2 assumes in the cell, how the enzyme moves three-dimensionally, and how the mutated LRRK2 contributes to nerve cells dying off. While the expertise of our colleagues in the USA lies in various imaging methods, here in Frankfurt we’ll develop chemical probes to localize and study LRRK2 in cells and we will produce recombinant LRRK2 variants that will help us to understand their three-dimensional structure.”
Co-Project Manager Florian Stengel, Professor for Cellular Proteostasis at the University of Konstanz, says: “In the framework of this project, we here in Konstanz want to identify the cellular interaction partners of LRRK2. In this way, we’ll be able to complete our picture of its cellular role and thus make it possible to develop a drug against LRRK2 mutated Morbus Parkinson.”
Research publication reporting the first three-dimensional structure of the LKKR2 protein:
C K Deniston, J Salogiannis, S Mathea, D M Snead, I Lahiri, M Matyszewski, O Donosa, R Watanabe, J Böhning, A K Shiau, S Knapp, E Villa, S L Reck-Peterson, A E Leschziner. Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction. Nature, 19 August 2020, doi: 10.1038/s41586-020-2673-2. Link to paper ...
Stefan Knapp, Buchmann Institute for Molecular Life Sciences and Institute for Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt/Main, Germany, email@example.com, knapp(at)pharmchem.uni-frankfurt.de
Florian Stengel, Department of Biology / Laboratory of Cellular Proteostasis and Mass Spectrometry, University of Konstanz, Germany, florian.stengel(at)uni-konstanz.de